<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297683</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003518</org_study_id>
    <nct_id>NCT04297683</nct_id>
  </id_info>
  <brief_title>HEALEY ALS Platform Trial - Master Protocol</brief_title>
  <official_title>HEALEY ALS Platform Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit E. Cudkowicz, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial&#xD;
      evaluating the safety and efficacy of investigational products for the treatment of ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial&#xD;
      evaluating the safety and efficacy of investigational products for the treatment of ALS. This&#xD;
      trial is designed as a perpetual platform trial. This means that there is a single Master&#xD;
      Protocol dictating the conduct of the trial.&#xD;
&#xD;
      In this trial, multiple investigational products for ALS will be tested simultaneously or&#xD;
      sequentially. Each investigational product will be tested in a regimen. Each regimen consists&#xD;
      of a placebo-controlled trial, meaning that the active investigational product and matching&#xD;
      placebo will be tested in each regimen.&#xD;
&#xD;
      The additional details that govern the testing of each investigational product will be&#xD;
      summarized in separate regimen-specific appendices (RSAs). Each regimen will have a separate&#xD;
      ClinicalTrials.gov posting, which will include specific information about the regimen. All&#xD;
      regimen-specific outcome measures will be detailed in each regimen posting.&#xD;
&#xD;
      Participants will have an equal chance to be randomized to all regimens that are active at&#xD;
      the time of screening. Once randomized to a regimen, participants will be randomized in a 3:1&#xD;
      ratio to either study drug or placebo.&#xD;
&#xD;
      The following regimens are active in the trial:&#xD;
&#xD;
      Regimen A - Zilucoplan Regimen B - Verdiperstat Regimen C - CNM-Au8 Regimen D - Priodopidine&#xD;
&#xD;
      New regimens will be continuously added as new investigational products become available. The&#xD;
      HEALEY ALS Platform Trial will enroll additional participants as each new regimen is&#xD;
      available.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>As new investigational products become available, additional regimens will be added to the HEALEY ALS Platform Trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Function</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in respiratory function over time as measured by Slow Vital Capacity (SVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Comparison of rate of occurrence between groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Regimen A - Zilucoplan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomized to receive either active zilucoplan or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B - Verdiperstat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomized to receive either active verdiperstat or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C - CNM-Au8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomized to receive either active CNM-Au8 or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D - Pridopidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are randomized to receive either active Pridopidine or matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zilucoplan</intervention_name>
    <description>Drug: Zilucoplan&#xD;
Administration: Subcutaneous injection&#xD;
Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight</description>
    <arm_group_label>Regimen A - Zilucoplan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verdiperstat</intervention_name>
    <description>Drug: Verdiperstat&#xD;
Administration: Oral&#xD;
Dose: 600mg twice daily</description>
    <arm_group_label>Regimen B - Verdiperstat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNM-Au8</intervention_name>
    <description>Drug: CNM-Au8&#xD;
Administration: Oral&#xD;
Dose: 30 mg or 60 mg daily</description>
    <arm_group_label>Regimen C - CNM-Au8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pridopidine</intervention_name>
    <description>Drug: Pridopidine&#xD;
Administration: Oral&#xD;
Dose: 45mg twice daily</description>
    <arm_group_label>Regimen D - Pridopidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported&#xD;
             probable, or definite ALS defined by revised El Escorial criteria.&#xD;
&#xD;
          2. Age 18 years or older.&#xD;
&#xD;
          3. Capable of providing informed consent and complying with study procedures, in the SI's&#xD;
             opinion.&#xD;
&#xD;
          4. Time since onset of weakness due to ALS ≤ 36 months at the time of the Master Protocol&#xD;
             Screening Visit.&#xD;
&#xD;
          5. Vital Capacity ≥ 50% of predicted capacity for age, height, and sex at the time of the&#xD;
             Master Protocol Screening Visit measured by Slow Vital Capacity (SVC), or, if required&#xD;
             due to pandemic-related restrictions, Forced Vital Capacity (FVC).&#xD;
&#xD;
          6. Participants must either not take riluzole or be on a stable dose of riluzole for ≥ 30&#xD;
             days prior to the Master Protocol Screening Visit. Riluzole-naïve participants are&#xD;
             permitted in the study.&#xD;
&#xD;
          7. Participants must either not take edaravone or have completed at least one cycle of&#xD;
             edaravone prior to the Master Protocol Screening Visit. Edaravone-naïve participants&#xD;
             are permitted in the study.&#xD;
&#xD;
          8. Participants must have the ability to swallow pills and liquids at the time of the&#xD;
             Master Protocol Screening Visit and, in the SI's opinion, have the ability to swallow&#xD;
             for the duration of the study.&#xD;
&#xD;
          9. Geographically accessible to the site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant unstable medical condition (other than ALS) that would pose a&#xD;
             risk to the participant, according to SI's judgment (e.g., cardiovascular instability,&#xD;
             systemic infection, untreated thyroid dysfunction, or clinically significant&#xD;
             laboratory abnormality or EKG changes).&#xD;
&#xD;
             Lab abnormalities include, but are not limited to: Hemoglobin &lt; 10 g/dL, White Blood&#xD;
             Cells &lt; 3.0 x 103/mm3, Neutrophils, Absolute ≤ 1000/mm3, Eosinophilia (absolute&#xD;
             eosinophil count of ≥ 500 eosinophils per microliter), low platelet counts (&lt; 150 x&#xD;
             109 per liter), alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&#xD;
             greater than 3 times the upper limit of normal (ULN), eGFR &lt; 30 mL/min/1.73m2,&#xD;
             thyroid-stimulating hormone (TSH) levels &gt;10 mIU/L or &lt;0.01 mIU/L.&#xD;
&#xD;
          2. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance&#xD;
             abuse that would impair ability of the participant to provide informed consent, in the&#xD;
             SI's opinion.&#xD;
&#xD;
          3. Active cancer or history of cancer, except for the following: basal cell carcinoma or&#xD;
             successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ,&#xD;
             prostatic carcinoma in situ, or other malignancies curatively treated and with no&#xD;
             evidence of disease recurrence for at least 3 years.&#xD;
&#xD;
          4. Use of investigational treatments for ALS (off-label use or active participation in a&#xD;
             clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior&#xD;
             to the Master Protocol Screening Visit.&#xD;
&#xD;
          5. Exposure at any time to any gene therapies under investigation for the treatment of&#xD;
             ALS (off-label use or investigational).&#xD;
&#xD;
          6. If female, breastfeeding, known to be pregnant, planning to become pregnant during the&#xD;
             study, or of child-bearing potential and unwilling to use effective contraception for&#xD;
             the duration of the trial and for 3 months, or longer as specified in each RSA, after&#xD;
             discontinuing study treatment.&#xD;
&#xD;
          7. If male of reproductive capacity, unwilling to use effective contraception for the&#xD;
             duration of the trial and for 3 months, or longer as specified in each RSA, after&#xD;
             discontinuing study treatment.&#xD;
&#xD;
          8. Anything that would place the participant at increased risk or preclude the&#xD;
             participant's full compliance with or completion of the study, in the SI's opinion.&#xD;
&#xD;
          9. If a participant is being re-screened, the disqualifying condition has not been&#xD;
             resolved, or the mandatory wash-out duration has not occurred.&#xD;
&#xD;
         10. For those participating in the optional CSF collection, contraindication to undergoing&#xD;
             a lumbar puncture (LP) in the SI's opinion. Participants undergoing the LP must not be&#xD;
             currently taking anticoagulation medications such as warfarin that would be a&#xD;
             contraindication to LP; aspirin and non-steroidal anti-inflammatories are allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit Cudkowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HEALEY Center for ALS at Massachusetts General Hospital</last_name>
    <phone>833-425-8257 (HALT ALS)</phone>
    <email>healeyalsplatform@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessie Duncan</last_name>
      <email>fulton.research@dignityhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Borg</last_name>
      <email>dborg@llu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salma Akhter</last_name>
      <email>salma.akhter@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia Mostowy</last_name>
      <email>GroupNeuromuscularResearch@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Overton</last_name>
      <email>jtoverto@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Forbes Norris MDA/ALS Research Center, California Pacific Medical Cente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marguerite Engel</last_name>
      <email>engelm@cpmcri.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenna Baines</last_name>
      <email>NeurologyResearchPartners@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Care</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Cartwright</last_name>
      <email>ncartwright@hfsc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phil Smith Neuroscience Institute at Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donovan Mott</last_name>
      <email>donovan.mott@holy-cross.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Steshyn</last_name>
      <email>jennifer.steshyn@neurology.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jany Paulett</last_name>
      <email>Paulett.Jany@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Levy</last_name>
      <phone>888-413-9315</phone>
      <email>alsresearch@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Shaw</last_name>
      <email>jessshaw@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arish Jamil</last_name>
      <email>arish.jamil@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Joslin</last_name>
      <email>ben.joslin@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shail Bhatnagar</last_name>
      <email>sbhatnagar@neurology.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harika Anedal Kekinagath</last_name>
      <email>harika-anedalkekinagath@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katheryn Jennens</last_name>
      <email>kjennens2@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Blood</last_name>
      <email>stuart.blood@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Edmond</last_name>
      <email>alsresearch@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikram Nambiar</last_name>
      <email>vnambiar@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Riley</last_name>
      <email>kriley15@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Hevert</last_name>
      <phone>617-643-3902</phone>
      <email>MGHsiteHealeyPlatform@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilda Gutierrez</last_name>
      <email>BIDMCHealeyALSPlatformTrial@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>North Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Douthwright</last_name>
      <email>Catherine.Douthwright@umassmed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayna Duell</last_name>
      <email>jkballar@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverley Duthie</last_name>
      <email>BDUTHIE1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gallavin</last_name>
      <email>HealeyALS@spectrumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Twin Cities ALS Research Consortium</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Ferment</last_name>
      <email>ferm0016@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Denny</last_name>
      <email>denny.carol@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Care</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Taylor</last_name>
      <email>taylornat@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Brown</last_name>
      <email>susan.a.brown@health.slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Livigni</last_name>
      <email>als@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.C./Somnos Clinical Research</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Harper</last_name>
      <email>Desi@somnos.com</email>
    </contact>
    <contact_backup>
      <email>raharper@unmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn Hilz</last_name>
      <email>katelyn.hilz@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Breen</last_name>
      <email>Allison.L.Breen@hitchcock.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brixhilda Dedi</last_name>
      <email>bd2577@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lena Deb</last_name>
      <email>debl@upstate.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Ward</last_name>
      <email>ALSResearch@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Health Science</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mozhdeh Marandi</last_name>
      <email>mmarandi@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mackenzie Kaschalk</last_name>
      <email>MacKenzie.Kaschalk@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine Institute ALS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Adamo</last_name>
      <email>ashley.adamo@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Runk</last_name>
      <email>hrunk@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jefferson Weinberg ALS Center, Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Hansen</last_name>
      <email>stephanie.hansen@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Penn</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adreeja Guharay</last_name>
      <email>Adreeja.Guharay@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lewis Katz School of Medicine at Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Hatala</last_name>
      <email>kathleen.hatala@tuhs.temple.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Davis</last_name>
      <email>diana.davis@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Morgan</last_name>
      <email>tmorgan@texasneurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Applegate</last_name>
      <email>rgapplegate@houstonmethodist.org</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Mendoza</last_name>
      <email>pamendoza@houstonmethodist.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Kittrell</last_name>
      <email>kittrellp@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Wagoner</last_name>
      <email>MIW9B@hscmail.mcc.virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sissons-Ross</last_name>
      <email>lsissons@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Mejaki</last_name>
      <email>mmejaki@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Merit E. Cudkowicz, MD</investigator_full_name>
    <investigator_title>Chief, Neurology Department</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Placebo-Controlled</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Master Protocol</keyword>
  <keyword>Lou Gehrig's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

